Erik Wist

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

Gabriel N. Hortobágyi, Salomon M. Stemmer, Howard A. Burris et al. · New England Journal of Medicine · 2016 · 1.9K citations · Full text

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial

Ian Smith, Marion Procter, Richard D. Gelber et al. · The Lancet · 2007 · 1.5K citations

Breast Oncology, Medicine, Adjuvant Chemotherapy +6

Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial

Jonas Bergh, Tom Wiklund, Björn Erikstein et al. · The Lancet · 2000 · 342 citations

Breast Oncology, Oncology, High-risk Breast Cancer +7

Phase III Randomized Study Comparing Docetaxel Plus Trastuzumab With Vinorelbine Plus Trastuzumab As First-Line Therapy of Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: The HERNATA Study

Michael Andersson, Elisabeth Lidbrink, Karsten Bjerre et al. · Journal of Clinical Oncology · 2010 · 291 citations

Gonadal Hormones in Long-Term Survivors 10 Years after Treatment for Unilateral Testicular Cancer

Carina Nord, Trine Bjøro, Dag G. Ellingsen et al. · European Urology · 2003 · 195 citations

Infertility, Urology, Andrology +13